Sinjardi tablets, film-coated, 12.5 mg/1000 mg, No. 60 (10×6)

In stock: 2
$125.00

Composition

Active ingredients: empagliflozin, metformin hydrochloride;

1 tablet contains 5 mg of empagliflozin and 1000 mg of metformin hydrochloride or

12.5 mg of empagliflozin and 1,000 mg of metformin hydrochloride;

Inactive ingredients:

5 mg/1000 mg tablets: corn starch, copovidone, colloidal anhydrous silicon dioxide, magnesium stearate, Opadry® Yellow 02B220012 film coating;

Composition of the Opadry® Yellow 02B220012 film coating: hypromellose 2910, polyethylene glycol 400, titanium dioxide (E 171), yellow iron oxide (E 172), talc;

12.5 mg/1000 mg tablets: corn starch, copovidone, colloidal anhydrous silicon dioxide, magnesium stearate, Opadry® Purple 02B200006 film coating;

Composition of the Opadry® Purple 02B200006 film coating: hypromellose 2910, polyethylene glycol 400, titanium dioxide (E 171), black iron oxide (E 172), red iron oxide (E 172), talc.

Dosage Form

Film-coated tablets.

Main physical and chemical properties:

5 mg/1000 mg tablets: oval, biconvex, film-coated tablets, brownish-yellow in color, engraved with the “Boehringer Ingelheim” logo and “S5” on one side and “1000” on the other side;

12.5 mg/1000 mg tablets: oval, biconvex, film-coated tablets, purple-brown in color, engraved with the “Boehringer Ingelheim” logo and “S12” on one side and “1000” on the other side.

Pharmacotherapeutic group

Agents used in diabetes mellitus. Combination of oral hypoglycemic agents.

ATC code A10B D20.

Pharmacological properties

Pharmacodynamics.

Mechanism of action.

SINDJARDI combines two hypoglycemic agents designed to improve glycemic control in patients with type 2 diabetes, whose mechanisms of action complement each other: empagliflozin, a sodium-dependent glucose cotransporter 2 (SODC2) inhibitor, and metformin hydrochloride, a member of the biguanide class.

Empagliflozin

Empagliflozin is a reversible, potent (IC50 1.3 nmol), and selective competitive inhibitor of the sodium-dependent glucose cotransporter type 2 (iSGLT2). Empagliflozin does not inhibit other glucose transporters that play an important role in delivering glucose to peripheral tissues, and is 5,000 times more selective for SGLT2 than for SGLT1, the primary transporter responsible for glucose absorption in the intestine. SGLT2 is highly expressed in the kidneys, whereas expression in other tissues is absent or very low. As the primary transporter, it is responsible for the reabsorption of glucose from the glomerular filtrate back into the bloodstream. In patients with type 2 diabetes and hyperglycemia, a greater amount of glucose is filtered and reabsorbed.

Empagliflozin improves glycemic control in patients with type 2 diabetes by reducing renal glucose reabsorption. The amount of glucose excreted by the kidneys via this glucuretic mechanism depends on blood glucose concentration and glomerular filtration rate (GFR). Inhibition of SGLT2 in patients with type 2 diabetes and hyperglycemia leads to increased glucose excretion in the urine.

In patients with type 2 diabetes, glucose excretion increased immediately after the first dose of empagliflozin and persisted throughout the 24-hour dosing interval. The increase in urinary glucose excretion persisted at the end of the 4-week treatment period and averaged approximately 78 g/day. The increase in urinary glucose excretion led to an immediate reduction in plasma glucose levels in patients with type 2 diabetes. In addition, empagliflozin increases sodium excretion, leading to osmotic diuresis and a reduction in intravascular volume.

Empagliflozin improves both fasting and postprandial plasma glucose levels. The mechanism of action of empagliflozin is independent of beta-cell function and the insulin signaling pathway, which helps reduce the risk of hypoglycemia. Improvements in markers of beta-cell function, including the homeostatic model assessment of beta-cell function (HOMA-β), have been observed. In addition, glucose excretion in the urine results in a caloric loss associated with reduced body fat and weight loss. The glucosuria observed with empagliflozin is accompanied by moderate diuresis, which may contribute to a sustained and moderate reduction in blood pressure. Glucosuria, natriuresis, and osmotic diuresis observed with empagliflozin may contribute to improved cardiovascular outcomes.

Metformin

Metformin belongs to the biguanide class of drugs, which have hypoglycemic properties and help lower blood glucose levels both when fasting and after meals. It does not stimulate insulin production and therefore does not cause hypoglycemia.

Metformin’s action is mediated by three mechanisms:

  • reduced glucose production in the liver by inhibiting gluconeogenesis and glycogenolysis;
  • increased muscle sensitivity to insulin, improved glucose uptake by peripheral tissues, and enhanced glucose utilization;
  • slowing the absorption of glucose in the intestine.

Metformin stimulates intracellular glycogen synthesis by acting on glycogen synthase. Metformin enhances the functional activity of all currently known types of glucose transporters.

Regardless of its effect on glycemia, metformin has a beneficial effect on human lipid metabolism. This has been demonstrated in controlled medium- and long-term clinical studies using metformin at therapeutic doses: metformin lowers total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides.

Clinical Efficacy and Safety

Improved glycemic control and a reduction in the incidence of cardiovascular disease and mortality are integral parts of the treatment of type 2 diabetes.

Treatment with empagliflozin in combination with metformin and other antidiabetic medications (pioglitazone, sulfonylureas, DPP-4 inhibitors, and insulin) or without them resulted in clinically significant improvements in HbA1c levels, fasting plasma glucose, body weight, and systolic and diastolic blood pressure. With the use of empagliflozin at a dose of 25 mg, the proportion of patients who achieved a target HbA1c level of less than 7% increased, and the number of patients requiring glycemic therapy decreased compared with treatment with empagliflozin 10 mg and placebo. The higher the baseline HbA1c level, the greater the reduction in HbA1c achieved with the drug.

In addition, empagliflozin as an adjunct to standard therapy reduces cardiovascular mortality and cardiovascular events in patients with type 2 diabetes.

Cardiovascular Outcomes

The double-blind, placebo--controlled EMPA-REG OUTCOME trial compared the efficacy of empagliflozin at doses of 10 mg and 25 mg with placebo as an adjunct to standard therapy in patients with type 2 diabetes and established cardiovascularcardiovascular disease.

Empagliflozin was superior to placebo in preventing death from cardiovascular disease, nonfatal myocardial infarction, or nonfatal stroke. This effect was driven by a significant reduction in cardiovascular mortality, with no substantial changes in the rates of nonfatal myocardial infarction or nonfatal stroke. The reduction in cardiovascular mortality was comparable for empagliflozin 10 mg and 25 mg (see graph below) and was confirmed by an improvement in overall survival (Table 1).

The effect of empagliflozin on the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke was largely independent of glycemic control or renal function (eGFR) and was generally consistent across eGFR categories up to an eGFR of 30 mL/min/1.73 m² in the EMPA-REG OUTCOME study.

The efficacy in preventing cardiovascular mortality has not been definitively established in patients who took empagliflozin concomitantly with DPP-4 inhibitors, or in Black patients, as the representation of these groups in the EMPA-REG OUTCOME study was limited.

Table 1

Treatment effect by primary endpoints, their components, and mortalitya

Endpoints Placebo Empagliflozinb
N 2,333 4,687
Time to first occurrence of a fatal event due to cardiovascular disease, nonfatal myocardial infarction, or nonfatal stroke, N (%) 282 (12.1) 490 (10.5)
Risk ratio compared to placebo (95.02% confidence interval (CI))* 0.86 (0.74; 0.99)
  • significance for benefit
0.0382
Death from cardiovascular disease, N (%) 137 (5.9) 172 (3.7)
Risk ratio compared to placebo (95% CI) 0.62 (0.49; 0.77)
  • value
< 0.0001
Nonfatal myocardial infarction, N (%) 121 (5.2) 213 (4.5)
Risk ratio compared to placebo (95% CI) 0.87 (0.70; 1.09)
  • value
0.2189
Nonfatal stroke, N (%) 60 (2.6) 150 (3.2)
Risk ratio compared to placebo (95% CI) 1.24 (0.92; 1.67)
  • value
0.1638
Overall mortality, N (%) 194 (8.3) 269 (5.7)
Risk ratio compared to placebo (95% CI) 0.68 (0.57; 0.82)
  • value
< 0.0001
Mortality not related to cardiovascular disease, N (%) 57 (2.4) 97 (2.1)
Risk ratio compared to placebo (95% CI) 0.84 (0.60; 1.16)

a Data from treated patients (i.e., patients who received at least one dose of the study drug).

b Combined results for the 10 mg and 25 mg doses of empagliflozin.

* Since the study results were included in an interim analysis, a two-sided 95.02% confidence interval is used, corresponding to a p-value < 0.0498 for statistical significance.

Fig. 1. Time to death from cardiovascular disease in the EMPA-REG OUTCOME study

Heart failure requiring hospitalization

In the EMPA-REG OUTCOME study, empagliflozin reduced the risk of heart failure requiring hospitalization compared with placebo (empagliflozin group—2.7%; placebo group—4.1%; OR 0.65, 95% CI 0.50–0.85).

Nephropathy

In the EMPA-REG OUTCOME study, when assessing the time to the first episode of nephropathy, the OR was 0.61 (95% CI 0.53; 0.70) in the empagliflozin group (12.7%) compared with the placebo group (18.8%).

In addition, empagliflozin increased the risk (OR 1.82; 95% CI 1.40; 2.37) of developing persistent normo- or microalbuminuria (49.7%) in patients with macroalbuminuria at baseline compared with placebo (28.8%).

Children

The clinical efficacy and safety of empagliflozin (10 mg with the option to increase the dose to 25 mg) and linagliptin (5 mg) once daily were studied in children and adolescents aged 10 to 17 years with type 2 diabetes in a placebo-controlled study (DINAMO) over 26 weeks, with a safety monitoring period extended to 52 weeks. The primary treatment, in addition to diet and exercise, consisted of metformin (51%), a combination of metformin and insulin (40.1%), insulin (3.2%), or none of these medications (5.7%).

The adjusted mean changes in HbA1c at week 26 between empagliflozin (N = 52) and placebo (N = 53) were 0.84% and were clinically and statistically significant (95% CI −1.50, −0.19; p = 0.0116). In addition, treatment with empagliflozin, compared with placebo, resulted in a clinically significant adjusted mean change in fasting plasma glucose (FPG) of –35.2 mg/dL (95% CI –58.6, –11.7) (–1.95 mmol/L (–3.25, –0.65)). These figures were -0.76% (95% CI -1.45%, -0.08%) for HbA1c and -38.28 mg/dL (95% CI from –60.47 to –16.10) for (GPN) in the metformin subgroup (N = 48 empagliflozin, N = 47 placebo).

Pharmacokinetics.

SINDJARDI

Results from bioequivalence studies involving healthy volunteers indicate that the combination drug SINDJARDI (empagliflozin/metformin hydrochloride) in the form of 5 mg/1000 mg and 12.5 mg/1000 mg are bioequivalent to the corresponding doses of empagliflozin and metformin in separate tablets taken simultaneously.

Administration of empagliflozin/metformin at a dose of 12.5 mg/1000 mg after a meal resulted in a 9% decrease in AUC and a 28% decrease in Cmax in the empagliflozin group compared with administration on an empty stomach. In the metformin group, AUC decreased by 12% and Cmax decreased by 26% compared with administration on an empty stomach. The observed effect of food on empagliflozin and metformin is not considered clinically significant. However, since metformin is recommended to be taken with food,

SINDJARDI is also recommended to be taken with food.

Empagliflozin

Absorption

The pharmacokinetics of empagliflozin have been extensively studied in healthy volunteers and patients with type 2 diabetes. Following oral administration, empagliflozin was rapidly absorbed, with peak plasma concentrations observed at a mean tmax of 1.5 hours after dosing. Thereafter, plasma concentrations declined in a biphasic manner, with a rapid distribution phase and a relatively slow terminal phase. The mean steady-state AUC and Cmax in plasma were 1,870 nmol/h and 259 nmol/L for empagliflozin 10 mg and 4,740 nmol/h and 687 nmol/L, respectively, when empagliflozin 25 mg was administered once daily. The systemic exposure to empagliflozin increased proportionally with the dose. The pharmacokinetic parameters of empagliflozin at rest following a single dose were similar, indicating linear pharmacokinetics over time. There was no clinically significant difference in the pharmacokinetics of empagliflozin between healthy volunteers and patients with type 2 diabetes.

The pharmacokinetics of empagliflozin were compared in healthy volunteers when administered at doses of 5 mg twice daily and 10 mg once daily. The total 24-hour exposure (AUCSS) of empagliflozin when administered at a dose of 5 mg twice daily was similar to that when administered at a dose of 10 mg once daily. As expected, empagliflozin 5 mg twice daily resulted in a lower Cmax and higher minimum plasma concentrations (Cmin) of empagliflozin compared with 10 mg once daily.

Administration of 25 mg of empagliflozin after a high-calorie, high-fat meal resulted in a slight reduction in its effect; AUC decreased by approximately 16%, and Cmax by approximately 37%, compared with administration on an empty stomach. This effect of food intake on the pharmacokinetics of empagliflozin is not considered clinically significant. Empagliflozin may be taken with or without food. Similar results were observed when the combined SINDJARDI tablets (empagliflozin/metformin) were taken with a high-calorie meal and a high-fat meal.

Distribution

The apparent volume of distribution at rest is 73.8 L, based on pharmacokinetic analysis in subjects. Following administration of an oral solution of [14C]-empagliflozin to healthy volunteers, erythrocyte distribution was approximately 37%, and plasma protein binding was 86%.

Biotransformation

No significant metabolites of empagliflozin were detected in human plasma. The most common metabolites are three glucuronide conjugates (2-, 3-, and 6-O-glucuronide). The systemic exposure of each metabolite accounted for less than 10% of the total drug-bound material. In vitro studies indicate that the primary route of empagliflozin metabolism in humans is glucuronidation by the uridine 5’-diphosphoglucuronosyltransferases UGT2B7, UGT1A3, UGT1A8, and UGT1A9.

Elimination

Based on the results of pharmacokinetic analysis in subjects, the apparent terminal half-life of empagliflozin is 12.4 hours, and the apparent oral clearance is 10.6 L/h. Inter-subject variability and intra-subject variability in the oral clearance of empagliflozin were 39.1% and 35.8%, respectively. With once-daily dosing, steady-state plasma concentrations of empagliflozin were achieved by the 5th dose. Based on the half-life, up to 22% accumulation (relative to plasma AUC) was observed at steady state. Following administration of an oral solution of [14C]-empagliflozin to healthy volunteers, approximately 96% of the radioactivity associated with the drug was excreted in the feces (41%) or urine (54%). The parent drug in its unchanged form accounted for the majority of the drug-related radioactivity excreted in the feces. The parent drug in its unchanged form accounted for approximately half of the drug-related radioactivity excreted in the urine.

Special Patient Populations

Renal Impairment

In patients with mild, moderate, or severe renal impairment (creatinine clearance < 30–< 90 mL/min) and in patients with renal failure / end-stage renal disease (ESRD), the AUC of empagliflozin increased by approximately 18%, 20%, 66%, and 48%, respectively, compared with subjects with normal renal function. Peak plasma levels of empagliflozin were similar in patients with moderate renal impairment and renal insufficiency/ESRD compared with subjects with normal renal function. Peak plasma levels of empagliflozin were approximately 20% higher in patients with mild and severe renal impairment compared with subjects with normal renal function. Based on the results of a pharmacokinetic analysis in subjects, the apparent oral clearance of empagliflozin decreased as creatinine clearance decreased, resulting in an increase in the drug’s effect.

Hepatic Impairment

In patients with mild, moderate, and severe hepatic impairment according to the Child–Pugh classification, the AUC of empagliflozin increased by approximately 23%, 47%, and 75%, and Cmax increased by approximately 4%, 23%, and 48%, respectively, compared with subjects with normal liver function.

Body Mass Index

Body mass index (BMI) had no clinically significant effect on the pharmacokinetics of empagliflozin. AUC was 5.82%, 10.4%, and 17.3% lower in patients with a BMI of 30, 35, and 45 kg/m², respectively, compared with patients with a body mass index of 25 kg/m².

Gender

Gender had no clinically significant effect on the pharmacokinetics of empagliflozin.

Race

AUC was 13.5% higher in patients of Mongoloid descent with a body mass index of 25 kg/m² compared with patients of other races with a body mass index of 25 kg/m².

Elderly Patients

Age had no clinically significant effect on the pharmacokinetics of empagliflozin.

Children

A Phase 1 pediatric study investigated the pharmacokinetics and pharmacodynamics of empagliflozin (5 mg, 10 mg, and 25 mg) in children and adolescents aged ≥ 10–<18 years with type 2 diabetes. The pharmacokinetic and pharmacodynamic data obtained were consistent with those in adults.

A Phase 3 pediatric study investigated the pharmacokinetics and pharmacodynamics (change in HbA1c from baseline) of empagliflozin at a dose of 10 mg, with a possible increase to 25 mg, in children and adolescents aged 10 to 17 years with type 2 diabetes. The observed exposure-response relationship was generally comparable in adults and in children and adolescents. Following oral administration, the exposure to empagliflozin was within the range observed in adult patients.

The observed geometric mean trough concentrations and geometric mean concentrations 1.5 hours after dosing at steady state were 26.6 nmol/L and 308 nmol/L for 10 mg of empagliflozin once daily and 67.0 nmol/L and 525 nmol/L for 25 mg of empagliflozin once daily.

Metformin

Absorption

Following oral administration of a dose of metformin, the maximum concentration (Tmax) is reached after 2.5 hours. The absolute bioavailability of metformin hydrochloride in 500 mg or 850 mg tablets in healthy volunteers is approximately 50–60%. Following oral administration, the unabsorbed fraction excreted in the feces was 20–30%. Following oral administration, the absorption of metformin hydrochloride is saturable and incomplete. The absorption of metformin hydrochloride is considered nonlinear. When the recommended doses and dosing regimen for metformin are followed, steady-state plasma concentrations are reached within 24–48 hours and generally amount to less than 1 μg/mL. According to data from controlled clinical trials, the maximum plasma concentration of metformin (Cmax) did not exceed 5 μg/mL, even when maximum doses were administered.

Food reduces the extent of and slightly delays the absorption of metformin. Following administration of 850 mg of metformin hydrochloride, a 40% reduction in its peak plasma concentration was observed, a 25% decrease in AUC (area under the curve), and a 35-minute delay in reaching peak plasma concentration. The clinical significance of these changes is unknown.

Distribution

Binding to plasma proteins is negligible. Metformin enters red blood cells. The peak concentration in blood is lower than that in plasma and is reached in approximately the same amount of time. Red blood cells most likely represent a secondary compartment of distribution. The mean volume of distribution (Vd) ranged from 63 to 276 liters.

Biotransformation

Metformin is excreted in the urine unchanged. No metabolites have been detected in humans.

Excretion

The renal clearance of metformin is >400 mL/min, indicating that metformin is eliminated via glomerular filtration and tubular secretion. Following oral administration, the apparent terminal elimination half-life is approximately 6.5 hours.

In patients with impaired renal function, renal clearance decreases in proportion to creatinine clearance; consequently, the terminal elimination half-life is prolonged, leading to increased plasma metformin levels.

Special Patient Populations

Children

Single-dose studies: Following administration of single doses of 500 mg metformin hydrochloride, the pharmacokinetic profile in children was comparable to that observed in healthy adult patients.

Multiple-dose studies: Following repeated doses of 500 mg twice daily for 7 days, the peak plasma concentration (Cmax) and systemic exposure (AUC0-t) in children were reduced by approximately 33% and 40%, respectively, compared with those in adult patients with diabetes who received repeated doses of 500 mg twice daily for 14 days. Since the dose is determined individually based on glycemic control, the clinical significance of these data is considered limited.

Indications

SINJARDI is indicated for adults and children aged 10 years and older for the treatment of type 2 diabetes as an adjunct to diet and exercise:

  • if the maximum tolerated dose of metformin alone is insufficient;
  • if metformin in combination with other antidiabetic medications does not provide adequate glycemic control;
  • if patients are already receiving therapy with a combination of empagliflozin and metformin as separate medications.

For study results on the use of combinations, effects on glycemic control, and cardiovascular disease, see the sections “Special Considerations for Use,” “Drug Interactions and Other Interactions,” and “Pharmacological Properties.”

Contraindications

  • Hypersensitivity to the active ingredients or to any of the excipients;
  • any type of metabolic acidosis (lactic acidosis, diabetic ketoacidosis) (see the “Special Considerations for Use” section);
  • diabetic precoma;
  • severe renal insufficiency (eGFR < 30 mL/min/1.73 m²) (see the “Special Considerations” and “Dosage and Administration” sections);
  • acute conditions that may alter renal function, such as dehydration, severe infection, or shock (see sections “Adverse Reactions” and “Special Precautions for Use”);
  • acute or chronic conditions that may cause tissue hypoxia: cardiac or respiratory failure, recent myocardial infarction, shock (see the “Special Considerations” section);
  • liver failure, acute alcohol intoxication, alcoholism (see the sections “Dosage and Administration” and “Drug Interactions and Other Interactions”).

Interactions with Other Medications and Other Types of Interactions

Concomitant administration of multiple doses of empagliflozin and metformin does not significantly alter either the pharmacokinetics of empagliflozin or the pharmacokinetics of metformin in healthy volunteers.

No interaction studies have been conducted with SINDJARDI and other medications. The data presented reflect the known information for each active ingredient separately.

Empagliflozin

Pharmacodynamic Interactions

Diuretics

Empagliflozin may enhance the diuretic effect of thiazide and loop diuretics and increases the risk of dehydration and hypotension (see the “Special Considerations” section).

Insulin and insulin secretagogues

Insulin and insulin secretagogues, such as sulfonylureas, increase the risk of hypoglycemia. Therefore, a reduction in the dose of insulin or insulin secretion stimulants may be necessary to reduce the risk of hypoglycemia when used in combination with empagliflozin (see sections “Dosage and Administration” and “Adverse Reactions”).

Pharmacokinetic Interactions

Effect of Other Medications on Empagliflozin

In vitro data indicate that the primary route of empagliflozin metabolism in humans is glucuronidation by the uridine-5’-diphosphoglucuronosyltransferases UGT1A3, UGT1A8, UGT1A9, and UGT2B7. Empagliflozin is a substrate for the human uptake transporters OAT3, OATP1B1, and OATP1B3, but not for OAT1 or OCT2. Empagliflozin is a substrate for P-glycoprotein (P-gp) and breast cancer resistance protein.

Concomitant use of empagliflozin with probenecid, an inhibitor of uridine diphosphoglucuronosyltransferases (UGTs) and OAT3, resulted in a 26% increase in the peak plasma concentration of empagliflozin (Cmax) and a 53% increase in the area under the concentration-time curve (AUC). These changes were not considered clinically significant.

The effect of UGT induction (by rifampicin or phenytoin) on empagliflozin has not been studied. Concomitant use with known UGT enzyme inducers is not recommended due to the potential risk of reduced efficacy. If concomitant use with UGT enzyme inducers is necessary, it is advisable to monitor glycemic control to assess the effect on SINJARDI.

An in vitro interaction study with gemfibrozil, an inhibitor of the OAT3 and OATP1B1/1B3 transporters, showed that following concomitant administration, the Cmax of empagliflozin increased by 15%, while AUC decreased by 59%. These changes were not considered clinically significant.

Inhibition of the OATP1B1/1B3 transporters during concomitant use with rifampicin resulted in a 75% increase in Cmax and a 35% increase in the AUC of empagliflozin. These changes were not considered clinically significant.

The effect of empagliflozin when co-administered with verapamil, a P-gp inhibitor, was similar to that when empagliflozin was administered alone. This indicates that P-gp inhibition has no clinically significant effect on empagliflozin.

Interaction studies indicate that the pharmacokinetics of empagliflozin are not affected by concomitant administration of metformin, glimepiride, pioglitazone, sitagliptin, linagliptin, warfarin, verapamil, ramipril, simvastatin, torasemide, or hydrochlorothiazide.

Effect of empagliflozin on other medications

Empagliflozin may increase renal excretion of lithium and lower blood lithium levels. After starting empagliflozin or changing the dose, serum lithium concentrations should be monitored more frequently. The patient should be referred to the prescribing physician to monitor serum lithium concentrations.

Based on in vitro studies, empagliflozin does not inhibit, inactivate, or induce CYP450 isoforms. Empagliflozin does not inhibit UGT1A1, UGT1A3, UGT1A8, UGT1A9, or UGT2B7. Drug-drug interactions involving major CYP450 or UGT isoforms between empagliflozin and concomitantly administered substrates of these enzymes are considered unlikely.

Empagliflozin does not inhibit P-gp at therapeutic doses. Based on in vitro studies, it is unlikely that empagliflozin will interact with active substances that are P-gp substrates. Concomitant use of digoxin, a P-gp substrate, and empagliflozin resulted in a 6% increase in AUC and a 14% increase in Cmax of digoxin. These changes were not considered clinically significant.

Empagliflozin does not inhibit human uptake transporters such as OAT3, OATP1B1, and OATP1B3, in vitro at clinically relevant concentrations; therefore, drug-drug interactions with substrates of these uptake transporters are considered unlikely.

Results from interaction studies conducted in healthy volunteers indicate that empagliflozin has no clinically significant effect on the pharmacokinetics of metformin, glimepiride, pioglitazone, sitagliptin, linagliptin, simvastatin, warfarin, ramipril, digoxin, diuretics, and oral contraceptives.

Metformin

Combinations Not Recommended

Alcohol

Alcohol intoxication is associated with an increased risk of lactic acidosis (especially in cases of fasting, malnutrition, or hepatic insufficiency).

Organic Cation Transporters (OCTs)

Metformin is a substrate for two transporters—OCT1 and OCT2.

Concomitant use of metformin:

  • with OCT1 inhibitors (such as verapamil) may reduce the effectiveness of metformin;
  • with OCT1 inducers (such as rifampicin) may increase gastrointestinal absorption and the effectiveness of metformin;
  • with OCT2 inhibitors (such as cimetidine, dolutegravir, ranolazine, trimethoprim, vandetanib, and isavuconazole) may reduce the renal elimination of metformin and, therefore, lead to increased plasma concentrations of metformin;
  • with OCT1 and OCT2 inhibitors (such as crizotinib, olaparib), may alter the efficacy and renal elimination of metformin.

Plasma metformin concentrations may increase when the above-mentioned drugs are taken concomitantly with metformin; therefore, caution is advised, especially in patients with impaired renal function. If necessary, the metformin dose may be adjusted, as OCT inhibitors/inducers may alter the efficacy of metformin (see the sections “Special Considerations” and “Dosage and Administration”).

Iodine-containing contrast media

Metformin should be discontinued prior to or during the duration of the examinations. Treatment should not be resumed until at least 48 hours after the examinations, provided that renal function has been confirmed to be stable; see the sections “Dosage and Administration” and “Special Safety Precautions.”

Combinations to Be Used with Caution

Certain medications may adversely affect renal function (e.g., NSAIDs, including cyclooxygenase-II inhibitors, ACE inhibitors, angiotensin II receptor antagonists, and diuretics, particularly loop diuretics), which may increase the risk of lactic acidosis. When such medications are used in combination with metformin, renal function should be closely monitored.

Glucocorticoids (administered systemically or topically), beta-2 agonists, and diuretics have their own hyperglycemic properties. Patients should be informed of this and have their blood glucose levels checked more frequently, especially at the start of treatment with these medications. If necessary, the dose of the antidiabetic medication should be adjusted during therapy with another drug, as well as upon its discontinuation.

Insulin and insulin secretagogues

Insulin and insulin secretagogues, such as sulfonylureas, increase the risk of hypoglycemia. Therefore, it may be necessary to reduce the dose of insulin or insulin secretagogues to minimize the risk of hypoglycemia when used concomitantly with metformin (see sections “Dosage and Administration” and “Adverse Reactions”).

Children

Interaction studies have been conducted only in adults.

Special Instructions for Use

General

Empagliflozin should not be used in patients with type 1 diabetes (see “Ketoacidosis” in the “Special Precautions for Use” section).

Lactic acidosis

Lactic acidosis is a very rare but serious complication associated with a metabolic disorder that most often occurs in cases of acute renal impairment, cardiorespiratory disease, or sepsis. Metformin accumulates during acute renal impairment and increases the risk of lactic acidosis.

In case of dehydration (due to severe diarrhea or vomiting, fever, or reduced fluid intake), you should temporarily stop taking metformin and consult a doctor.

Medications that may cause acute renal impairment (e.g., antihypertensive agents, diuretics, nonsteroidal anti-inflammatory drugs (NSAIDs)) should be used with caution in patients receiving metformin. Other risk factors for lactic acidosis include alcohol abuse, liver failure, poorly controlled diabetes mellitus, ketosis, prolonged fasting, any conditions associated with hypoxia, as well as concomitant use of medications that may cause lactic acidosis (see the “Contraindications” and “Drug Interactions and Other Interactions” sections).

Patients and/or their caregivers should be informed of the risk of developing lactic acidosis. Lactic acidosis is characterized by acidotic dyspnea, abdominal pain, muscle spasms, asthenia, and hypothermia, followed by coma. If the symptoms listed above occur, patients should stop taking metformin and seek medical attention immediately. Laboratory diagnostic signs of lactic acidosis include a decrease in blood pH (< 7.35), elevated plasma lactate levels (> 5 mmol/L), as well as an increased anion gap and lactate-to-pyruvate ratio.

Diabetic Ketoacidosis

Rare cases of diabetic ketoacidosis (DKA), including life-threatening and fatal cases, have been reported during treatment with SGLT2 inhibitors (including empagliflozin). In several cases, DKA presented atypically, with only a moderate increase in blood glucose levels [below 14 mmol/L (250 mg/dL)]. It is unknown whether increasing the dose of empagliflozin affects the likelihood of DKA occurring.

The risk of DKA should be considered if nonspecific symptoms such as nausea, vomiting, loss of appetite, abdominal pain, excessive thirst, difficulty breathing, confusion, or unusual fatigue or drowsiness occur. If these symptoms occur, patients should be evaluated immediately for ketoacidosis, regardless of their blood glucose level.

Empagliflozin should be discontinued immediately in patients with suspected or diagnosed DKA.

If a patient is hospitalized for major surgical procedures or in the event of serious acute illnesses, treatment should be interrupted. Monitoring of ketone levels is recommended in these patients. Measurement of ketone levels in the blood is preferred over measurement in the urine. Treatment with empagliflozin may be resumed once ketone levels have normalized and the patient’s condition has stabilized.

Before starting empagliflozin, the patient’s medical history should be reviewed for factors that may indicate a predisposition to ketoacidosis.

Patients with impaired beta-cell function (e.g., type 2 diabetes mellitus with low C-peptide levels, latent autoimmune diabetes in adults, or a history of pancreatitis); patients with conditions leading to restricted food intake or severe dehydration; patients whose insulin dose is being reduced, and patients with increased insulin requirements due to acute illness, surgery, or alcohol abuse. SGLT2 inhibitors should be used with caution in these patients.

Resuming treatment with SGLT2 inhibitors in patients with DKA who were previously treated with SGLT2 inhibitors is not recommended unless another factor causing DKA has been clearly identified and eliminated.

SINJARDI should not be used in patients with type 1 diabetes. Data from a clinical trial involving patients with type 1 diabetes showed an increased incidence of DKA with 10 mg and 25 mg of empagliflozin as an adjunct to insulin compared with placebo.

Use of Iodine-Containing Contrast Media

Intravascular administration of iodinated contrast media may cause contrast-induced nephropathy. This may lead to metformin accumulation and increase the risk of lactic acidosis. Therefore, metformin treatment should be discontinued prior to or during the duration of such examinations. Treatment should not be resumed until at least 48 hours after the examinations and only if renal function tests confirm that renal function has stabilized (see the sections “Dosage and Administration” and “Drug Interactions and Other Interactions”).

Renal Impairment

Due to its mechanism of action, reduced renal function will result in decreased glycemic efficacy of empagliflozin. The empagliflozin/metformin fixed-dose combination is contraindicated in patients with an eGFR < 30 mL/min/1.73 m².

Use of the drug should be temporarily discontinued in the presence of factors that alter renal function (see the “Contraindications” section).

Monitoring of Renal Function

It is recommended that renal function be assessed as follows:

  • before starting empagliflozin/metformin and periodically during treatment, i.e., at least once a year (see the “Special Considerations for Use” section);
  • before starting any concomitant medication that may adversely affect renal function.

Cardiac Function

Patients with heart failure are at higher risk of developing hypoxia and renal failure. In patients with stable chronic heart failure, SINDJARDI may be used while monitoring cardiac and renal function. SINDJARDI is contraindicated in patients with acute or unstable heart failure due to its metformin content (see the “Contraindications” section).

Surgery

Metformin therapy should be discontinued during surgery involving general, spinal, or epidural anesthesia. Treatment with the drug may be resumed no earlier than 48 hours after surgery or the resumption of oral intake, and only after re-evaluation of renal function and confirmation of its stability.

Risk of Decreased Intracellular Fluid Volume

As a result of the action of SGLT2 inhibitors, osmotic diuresis accompanying drug-induced glucosuria may lead to a slight decrease in blood pressure (see the section “Pharmacological Properties. Pharmacodynamics”). Use with caution in patients for whom a decrease in blood pressure caused by empagliflozin may pose a risk, such as patients with a history of cardiovascular disease, patients (with a history of hypotension) receiving antihypertensive therapy, or patients aged 75 years or older.

If conditions that may lead to fluid loss develop (e.g., gastrointestinal disorders), patients receiving SINDJARDI should be carefully monitored for signs of decreased extracellular fluid volume (e.g., physical examination, blood pressure measurement, laboratory tests, including hematocrit levels) and may require electrolyte replacement. Consider temporarily discontinuing treatment with SINDJARDI until fluid volume is restored.

Elderly Patients

The effect of empagliflozin on urinary glucose excretion is associated with osmotic diuresis, which may affect hydration status. Patients aged 75 years and older are at increased risk of a decrease in extracellular fluid volume. Therefore, special attention should be paid to intracellular fluid volume when co-administering medications that may lead to its reduction (such as diuretics and ACE inhibitors).

Urinary Tract Infections

In postmarketing studies, cases of complications in the form of genitourinary tract infections, including pyelonephritis and urosepsis, have been observed in patients receiving empagliflozin (see the “Adverse Reactions” section). Consider temporarily discontinuing empagliflozin treatment in patients with complicated urinary tract infections.

Necrotizing perineal fasciitis (Fournier’s gangrene)

Cases of necrotizing perineal fasciitis (also known as Fournier’s gangrene) have been reported during postmarketing surveillance in women and men taking SGLT2 inhibitors. Fournier’s gangrene is a rare but serious and potentially life-threatening infection that requires urgent surgical intervention and antibiotic treatment.

Patients should be advised to seek immediate medical attention if they experience symptoms such as pain, tenderness, erythema, or swelling in the genital or perineal area, accompanied by fever or malaise. It should be noted that a urogenital infection or perineal abscess may precede necrotizing fasciitis. If Fournier’s gangrene is suspected, SINDJARDI should be discontinued and treatment initiated promptly (including administration of antibiotics and surgical debridement of the affected area).

Lower Limb Amputations

An increase in the incidence of lower limb amputations (primarily toes) was observed in long-term clinical trials with another SGLT2 inhibitor. It is unknown whether this is characteristic of the entire class of drugs. It is important to counsel all patients with diabetes on regular preventive care for their lower extremities.

Liver Damage

Cases of liver injury have been reported during clinical trials with empagliflozin. A causal relationship between the use of empagliflozin and liver injury has not been established.

Elevated hematocrit

Elevated hematocrit has been observed during treatment with empagliflozin (see the “Adverse Reactions” section).

Chronic Kidney Disease

There is experience with the use of empagliflozin for the treatment of diabetes mellitus in patients with chronic kidney disease (eGFR ≥ 30 mL/min/1.73 m²) with or without albuminuria. Patients with albuminuria may derive greater benefit from treatment with empagliflozin.

Urinalysis

Patients taking SINDJARDI are expected to test positive on a urine glucose test.

Interference with 1,5-Anhydroglucitol (1,5-AG) Levels

Monitoring glycemic control using 1,5-AG levels is not recommended, as 1,5-AG measurements are unreliable in patients taking SGLT2 inhibitors. Alternative methods of glycemic control are recommended.

Vitamin B12

Metformin may lower vitamin B12 levels. The risk of low vitamin B12 levels increases with higher doses of metformin, longer duration of treatment, and/or the presence of risk factors known to cause vitamin B12 deficiency. If vitamin B12 deficiency is suspected (e.g., anemia or neuropathy), serum vitamin B12 levels should be monitored. Periodic monitoring of vitamin B12 levels may be necessary in patients with risk factors for vitamin B12 deficiency. Metformin therapy should be continued as long as it is well tolerated and there are no contraindications; appropriate corrective treatment for vitamin B12 deficiency should also be provided in accordance with current clinical guidelines.

Children

In the DINAMO study (see the “Pharmacological Properties. Pharmacodynamics”), the overall safety profile in children and adolescents was similar to the known safety profile in adults, and no significant differences were observed between the placebo and empagliflozin groups regarding patients’ growth or sexual maturation after 26 weeks of treatment. During a one-year controlled clinical trial, no effect of metformin on growth or sexual maturation was observed; however, there are no long-term data on growth and sexual maturation. Therefore, careful monitoring of metformin’s effects on these parameters is recommended in children taking metformin, especially in prepubertal children.

Children aged 10–12 years

Only 15 patients aged 10 to 12 years were included in controlled clinical trials of metformin involving children and adolescents.

The DINAMO study included 157 patients, 91% of whom received metformin as baseline therapy; 25 of these patients were aged 10 to 12 years.

Although the efficacy and safety of metformin in these children did not differ from those in older children and adolescents, metformin should be prescribed with caution to children aged 10 to 12 years.

Use during pregnancy or breastfeeding.

Pregnancy

There are no data on the use of this medication or empagliflozin in pregnant women. Some data suggest that the use of metformin in pregnant women is not associated with an increased risk of congenital anomalies.

If a patient is planning to become pregnant or is already pregnant, it is recommended that this medication not be used to treat diabetes. Such patients should be switched to insulin to maintain blood glucose levels as close to normal as possible, in order to reduce the risk of fetal malformations associated with abnormal blood glucose levels.

Breastfeeding

Metformin is excreted into breast milk. No adverse effects on newborns or infants whose mothers took the medication have been observed. There are no data on whether empagliflozin is excreted into human breast milk. A risk to newborns/infants cannot be ruled out.

This medication should not be used during breastfeeding.

Fertility

No studies have been conducted on the effects of this drug or empagliflozin on fertility in humans.

Effect on reaction time when driving or operating machinery.

SINJARDI has a negligible effect on reaction time when driving or operating machinery. Patients should be advised to take precautions to avoid hypoglycemia while driving or operating machinery, particularly when taking SINDJARDI in combination with sulfonylureas and/or insulin.

Dosage and Administration

Dosage

Adults with normal renal function (eGFR ≥ 90 mL/min/1.73 m²)

The recommended dose is 1 tablet twice daily. The dose should be individualized based on the patient’s current regimen, the efficacy and tolerability of the recommended daily dose of 10 mg or 25 mg of empagliflozin, while not exceeding the maximum recommended daily dose of metformin.

For patients who do not achieve adequate glycemic control with metformin alone or with metformin in combination with other antidiabetic medications

For patients who do not achieve adequate glycemic control with metformin alone or metformin in combination with other antidiabetic medications, the recommended starting dose of SINDJARDI is 5 mg of empagliflozin twice daily (10 mg daily) in addition to the current dose of metformin. For patients who tolerate a total daily dose of 10 mg of empagliflozin well and who require stricter glycemic control, the dose may be increased to 25 mg of empagliflozin per day (maximum daily dose of empagliflozin 25 mg).

If SINDJARDI is used in combination with sulfonylureas and/or insulin, consideration should be given to using sulfonylureas and/or insulin at lower doses, to reduce the risk of hypoglycemia (see sections “Interactions with Other Medications and Other Interactions” and “Adverse Reactions”).

For patients switching from combination therapy with empagliflozin and metformin as separate medications

For patients switching from separate doses of empagliflozin (total daily dose of 10 mg or 25 mg) and metformin to SINGARDI, it is recommended to start with the current daily dose of empagliflozin and metformin that they are currently taking or to start with the lowest appropriate therapeutic dose of metformin (see the “Composition” section for available dosages of the drug).

Missed Dose

If a dose is missed, it should be taken as soon as possible. Do not take a double dose of the medication on the same day.

Special Patient Populations

Renal impairment

The glycemic efficacy of empagliflozin depends on the patient’s renal function. To reduce cardiovascular risk as an adjunct to standard therapy, patients with an eGFR below 60 mL/min/1.73 m² should receive empagliflozin at a dose of 10 mg daily (see Table 2). Since the glycemic-lowering effect of empagliflozin is reduced in patients with moderate renal impairment and is likely absent in patients with severe renal impairment, if further glycemic control is needed, the addition of other antidiabetic agents should be considered in these patients.

See Table 2 for recommendations on dose adjustment based on eGFR or CrCL.

Estimated glomerular filtration rate (eGFR) should be assessed before initiating treatment with metformin-containing medications. Thereafter, assessment should be performed at least annually. In patients at increased risk of further progression of renal impairment and in elderly patients, renal function should be assessed more frequently, for example every 3–6 months.

If an appropriate dosage of SINDJARDI is not available, the individual components should be used separately instead of the fixed-dose combination.

For dosing recommendations in pediatric practice, see the “Children” section below.

Table 2

Dosage for Adult Patients with Impaired Renal Function

eGFR, mL/min/1.73 m², or CrCL, (mL/min) Metformin Empagliflozin
> 60 Maximum daily dose: 3,000 mg.

A dose reduction may be considered in cases of impaired renal function.

The starting dose is 10 mg.

For patients who tolerate the 10 mg dose and require additional glycemic control, the dose may be increased to 25 mg.

45 – <60 The maximum daily dose is 2,000 mg. The starting dose should not exceed half the maximum dose. Starting dose: 10 mg b.

Patients already taking empagliflozin should continue taking 10 mg.

30 – < 45 The maximum daily dose is 1,000 mg. The starting dose should not exceed half the maximum dose. The starting dose is 10 mg twice daily.

Patients already taking empagliflozin should continue taking 10 mg twice daily.

< 30

 

Metformin is contraindicated Empagliflozin is not recommended

a – see the sections “Special Considerations for Use,” “Adverse Reactions,” and “Pharmacological Properties: Pharmacokinetics and Pharmacodynamics.”

b – Patients with type 2 diabetes and cardiovascular disease.

Hepatic impairment

This medication should not be used in patients with hepatic insufficiency (see sections “Contraindications,” “Special Precautions for Use,” “Pharmacological Properties: Pharmacodynamics”).

Elderly patients

Given its mechanism of action, the reduced efficacy of empagliflozin is a consequence of impaired renal function. Since metformin is excreted by the kidneys and elderly patients are more likely to have impaired renal function, SINJARDI should be used with caution in this patient population. To prevent metformin-induced lactic acidosis, monitoring of renal function is necessary, particularly in elderly patients (see the “Contraindications” and “Special Precautions for Use” sections). In patients aged 75 years and older, the increased risk of decreased intravascular volume should be taken into account (see sections “Special Precautions for Use” and “Adverse Reactions”).

Dosage and Administration

SINDJARDI is administered twice daily with meals to reduce gastrointestinal side effects associated with metformin use. The tablets should be swallowed whole with water. All patients should continue to follow a diet with an appropriate distribution of carbohydrate intake throughout the day. Patients who are overweight should continue to follow a low-calorie diet.

Children.

The dosage should be individualized based on the patient’s current treatment regimen, the efficacy, and the tolerability of the therapy.

If empagliflozin is added to the treatment of patients already receiving metformin, the metformin dose should remain the same as the patient is currently taking. The recommended starting dose of empagliflozin is 5 mg twice daily (total daily dose of 10 mg). For patients who tolerate empagliflozin 5 mg twice daily well and require additional glycemic control, the dose may be increased to 12.5 mg twice daily (total daily dose of 25 mg).

If a patient is switched from separate empagliflozin and metformin tablets to SINDJARDI, the same daily dose of empagliflozin and metformin that is currently being taken should be maintained, or the nearest therapeutically acceptable dose of metformin should be used.

The maximum recommended daily dose of SINDJARDI is 25 mg of empagliflozin and 2,000 mg of metformin (see general information in the “Dosage and Administration” section).

There are no data on the use of this medication in children with an eGFR below 60 mL/min/1.73 m² or in children under 10 years of age.

Overdose

Symptoms

Empagliflozin

In controlled clinical trials, single doses of up to 800 mg of empagliflozin (equivalent to 32 times the maximum recommended daily dose) in healthy volunteers and multiple daily doses of up to 100 mg of empagliflozin (equivalent to 4 times the maximum recommended daily dose) in patients with type 2 diabetes did not cause any toxicity. Empagliflozin increased urinary glucose excretion, leading to an increase in urine volume. The observed increase in urine volume was not dose-dependent and was not clinically significant. There is no experience with doses above 800 mg in humans.

Metformin

No hypoglycemia was observed with metformin doses up to 85 g; however, cases of lactic acidosis have been reported under these circumstances. A significant overdose of metformin or concomitant risks may lead to lactic acidosis. Lactic acidosis is a condition requiring urgent medical attention and inpatient treatment (see the sections “Interactions with Other Medications and Other Types of Interactions” and “Special Considerations for Use”).

Treatment

In case of overdose, treatment should be initiated according to the patient’s clinical condition. Hemodialysis is the most effective method for removing lactate and metformin. The removal of empagliflozin by hemodialysis has not been studied.

Side Effects

The most common adverse reactions in clinical trials were hypoglycemia (when used with insulin and/or sulfonylureas) and gastrointestinal symptoms (nausea, vomiting, diarrhea, abdominal pain, and loss of appetite). In clinical studies, no additional adverse reactions were observed when empagliflozin was used as an adjunct to metformin compared with the adverse reactions observed when each component was used alone.

Adverse reactions are listed by organ system and frequency of occurrence: very common (≥ 1/10), common (≥ 1/100 – < 1/10), uncommon (≥ 1/1,000 – < 1/100), rarely (≥1/10,000 – < 1/1,000), very rarely (< 1/10,000), frequency unknown (frequency cannot be estimated from the available data).

Table 3

Adverse reactions observed during placebo-controlled trials and postmarketing use

Organ system Very common Common Uncommon Rare Very rarely
Infections and infestations Vaginal candidiasis, vulvovaginitis, balanitis, and other genital infections¹⁻²,

urinary tract infections (including

pyelonephritis and urosepsis)¹⁻²

Necrotizing fasciitis of the perineum

(Fournier’s gangrene)a

 

Metabolic and Gastrointestinal Disorders Hypoglycemia (when used concomitantly with sulfonylureas or insulin)1 Thirst²; vitamin B12 deficiency³,a Diabetic ketoacidosisa Lactic acidosis³
Neurological side effects Taste disturbances3
Vascular system Decreased interstitial fluid volume1,2,d
Gastrointestinal system Gastrointestinal symptoms3,4 Constipation
Hepatobiliary system Abnormalities in liver function tests³,

hepatitis³

Skin and subcutaneous tissue Itching (generalized)2,3,

rash

 

Urticaria, angioedema Erythema3
Renal and urinary tract disorders Increased urine output1,2 Dysuria2 Tubulointerstitial nephritis
Laboratory findings Elevated serum lipid levels2,b Elevated blood creatinine levels/decreased glomerular filtration rate, increased hematocrit

2, c

1 See below.

2 Adverse reactions observed with empagliflozin monotherapy.

3 Adverse reactions observed with metformin monotherapy.

4 Gastrointestinal symptoms, namely nausea, vomiting, diarrhea, abdominal pain, and loss of appetite, most often occur at the start of treatment and usually resolve spontaneously.

a See the “Special Considerations for Use” section.

b The mean percentage increase from baseline for empagliflozin 10 mg and 25 mg compared with placebo was, respectively, 5.0% and 5.2% for total cholesterol compared with 3.7%; HDL-cholesterol—4.6% and 2.7% compared with 0.5%; LDL-cholesterol—9.1% and 8.7% compared with 7.8%; triglycerides—5.4% and 10.8% compared with 12.1%.

c The mean changes in hematocrit from baseline for empagliflozin 10 mg and 25 mg compared with placebo were 3.6% and 4.0%, respectively, compared with 0%. In clinical trials, hematocrit levels returned to baseline after a 30-day follow-up period following discontinuation of treatment.

d Pooled data from empagliflozin studies involving patients with heart failure (half of whom had type 2 diabetes) showed a higher incidence of decreased interstitial fluid volume (“very common”: 11.4% for empagliflozin compared with 9.7% for placebo).

Description of Individual Adverse Reactions

Hypoglycemia

In the relevant studies, the incidence of hypoglycemia depended on baseline therapy and was similar with empagliflozin and placebo when used as an adjunct to metformin, as an adjunct to linagliptin and metformin, as well as when empagliflozin was used in combination with metformin in treatment-naive patients, compared with patients who had previously used empagliflozin and metformin as separate components and as an adjunct to standard therapy. An increase in incidence was observed when empagliflozin was administered as an adjunct to metformin and sulfonylurea (empagliflozin 10 mg: 16.1%, empagliflozin 25 mg: 11.5%, placebo: 8.4%) or as an add-on to metformin and insulin (empagliflozin 10 mg: 31.3%, empagliflozin 25 mg: 36.2%, and placebo: 34.7%).

Severe hypoglycemia (hypoglycemia requiring treatment)

The overall incidence of severe hypoglycemia in patients was low (<1%) and similar with empagliflozin and placebo as add-on therapy to metformin, as well as with the combination of empagliflozin and metformin in treatment-naive patients, compared with patients who had previously used empagliflozin and metformin as separate components and as an adjunct to standard therapy. Severe hypoglycemia was observed in 0.5%, 0%, and 0.5% of patients taking empagliflozin 10 mg, empagliflozin 25 mg, and placebo, respectively, when added to metformin and insulin. No cases of severe hypoglycemia were reported when used in combination with metformin and sulfonylurea, or as an adjunct to linagliptin and metformin.

Urinary Tract Infections

The overall incidence of urinary tract infections was higher in the group of patients taking metformin in combination with empagliflozin 10 mg (8.8%), compared with the group of patients receiving empagliflozin 25 mg (6.6%) or placebo (7.8%). As in the placebo group, urinary tract infections were observed more frequently with empagliflozin in patients with a history of chronic or recurrent urinary tract infections. The severity (mild, moderate, severe) of urinary tract infections was similar to that in patients receiving placebo. Urinary tract infections occurred more frequently in women receiving empagliflozin 10 mg compared with placebo, but were not observed with empagliflozin 25 mg. The incidence of urinary tract infections was lower in men.

Vaginal candidiasis, vulvovaginitis, balanitis, and other genital infections

Vaginal candidiasis, vulvovaginitis, balanitis, and other genital infections were reported more frequently in the group of patients taking metformin in combination with empagliflozin 10 mg (4.0%) and at a dose of 25 mg (3.9%), compared with patients in the placebo group (1.3%), and were observed more frequently in women receiving empagliflozin compared with placebo. The difference in incidence was less pronounced in men. Genital infections were mild or moderate in severity. No severe infections were reported.

Increased Urine Output

Given the mechanism of action, increased urine output (including pollakiuria, polyuria, and nocturia) was observed more frequently in patients taking metformin in combination with empagliflozin at a dose of 10 mg (3.0%) and at a dose of 25 mg (2.9%), compared with patients in the placebo group (1.4%) as an adjunct to metformin. Frequent urination was predominantly mild or moderate. The incidence of reported cases of nocturia was comparable in the placebo and empagliflozin groups (< 1%).

Decrease in Interstitial Fluid Volume

The overall incidence of a decrease in interstitial fluid volume (including the predefined terms: decreased blood pressure [ambulatory], decreased systolic blood pressure, dehydration, arterial hypotension, hypovolemia, orthostatic hypotension, and syncope) in patients taking metformin while receiving empagliflozin was low: 0.6% in the 10-mg empagliflozin group, 0.3% in the empagliflozin 25 mg group, and 0.1% in the placebo group. The effect of empagliflozin on urinary glucose excretion is associated with osmotic diuresis, which may affect the hydration status of patients aged 75 years and older. Among patients aged 75 years and older, dehydration was observed in one patient who was taking empagliflozin 25 mg as an adjunct to metformin.

Increased serum creatinine levels/decreased glomerular filtration rate

The overall incidence of increased serum creatinine and decreased glomerular filtration rate was similar with empagliflozin and placebo when used as an adjunct to metformin (increased serum creatinine: empagliflozin 10 mg: 0.5%, empagliflozin 25 mg: 0.1%, placebo: 0.4%; decrease in glomerular filtration rate: empagliflozin 10 mg: 0.1%, empagliflozin 25 mg: 0%, placebo: 0.2%).

Generally, in patients receiving empagliflozin as an adjunct to metformin, initial increases in creatinine levels and decreases in glomerular filtration rate during long-term treatment were transient or reversible after discontinuation of therapy.

In the EMPA-REG OUTCOME study, patients taking empagliflozin experienced an initial decrease in eGFR (mean: 3 mL/min/1.73 m²). Thus, eGFR was maintained throughout continuous treatment. The mean eGFR returned to baseline values after discontinuation of treatment, suggesting that severe hemodynamic disturbances may play a role in these changes in renal function.

Children

The DINAMO study included 157 children aged 10 years and older with type 2 diabetes, of whom 52 patients received empagliflozin, 52 received linagliptin, and 53 received placebo (see the “Pharmacological Properties. Pharmacodynamics” section). During the placebo-controlled phase, the most common adverse reaction to the drug was hypoglycemia (empagliflozin 10 mg and 25 mg, combined: 23.1%, placebo: 9.4%). None of these events were serious or required medical attention.

The overall safety profile in children was similar to that in adults with type 2 diabetes.

Reporting Suspected Adverse Reactions

Reporting adverse reactions after a drug’s approval is important. This allows for monitoring the benefit-risk balance of this drug. Healthcare and pharmaceutical professionals, as well as patients or their legal representatives, should report all cases of suspected adverse reactions and lack of efficacy of the drug through the Automated Pharmacovigilance Information System at the following link: https://aisf.dec.gov.ua.

Shelf life

3 years.

Storage conditions

Store in the original packaging at a temperature not exceeding 25 °C. Keep out of the reach of children.

Packaging

10 film-coated tablets per blister pack; 6 blister packs per cardboard box.

Manufacturer

Boehringer Ingelheim Pharma GmbH & Co. KG, Germany/

Boehringer Ingelheim Pharma GmbH & Co. KG, Germany.

Boehringer Ingelheim Hellas Single Member S.A., Greece/

Boehringer Ingelheim Hellas Single Member S.A., Greece.

PATHEON FRANCE, France/

PATHEON FRANCE, France.

Address

Binger Strasse 173, 55216 Ingelheim am Rhein, Germany/

Binger Strasse 173, 55216 Ingelheim am Rhein, Germany.

5th km Paiania-Markopoulo, Koropi, Attica, 19441, Greece/

5th km Paiania-Markopoulo, Koropi, Attica, 19441, Greece.

40 Boulevard de Champaret, Bourgoin-Jallieu, 38300, France/

40 Boulevard de Champaret, Bourgoin-Jallieu, 38300, France.